Hypertrophic cardiomyopathy and pregnancy

DOI: https://doi.org/10.29296/25877305-2021-08-04
Download full text PDF
Issue: 
8
Year: 
2021

Professor G. Ignatenko(1), MD, Corresponding Member of the National Academy of Medical Sciences
of Ukraine, Associate Professor G. Taradin(1, 2), Candidate of Medical Sciences; T. Kugler(1), Candidate of
Medical Sciences (1)M. Gorky Donetsk National Medical University, Donetsk, Donetsk People’s Republic/Ukraine
(2)V.K. Gusak Institute of Emergency and Restorative Surgery, Donetsk, Donetsk People’s Republic/Ukraine

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease. Owing to achievements in medicine over recent decades, the number of pregnancies in women with HCM is increasing and will continue to grow in the future. In most women with HCM, pregnancy proceeds without complications; however, during gestation, the risk of adverse cardiovascular events is increased, especially in symptomatic patients who had a high left ventricular outflow tract gradient, heart failure (HF), or arrhythmias before conception. A high functional class of HF prior to pregnancy is statistically significantly associated with an increased risk of cardiovascular complications during pregnancy or in the postpartum period. In this connection, a detailed cardiovascular system assessment in a patient with HCM is needed to determine the potential risks associated with pregnancy and childbirth and to develop an appropriate therapeutic strategy. The review presents the latest national and international guidelines for the diagnosis and management of pregnant women with HCM. It is emphasized that the clinical manifestations and diagnosis of HCM during pregnancy have a number of features and when prescribing medications, it is necessary to take into account their possible negative impact on the health of the mother and fetus.
Keywords: 
cardiology
obstetrics and gynecology
hypertrophic cardiomyopathy
pregnancy
left ventricular hypertrophy
cardiovascular diseases
heart failure
arrhythmias
atrial fibrillation

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Schaufelberger M. Cardiomyopathy and pregnancy. Heart. 2019; 105 (20): 1543–51. DOI: 10.1136/heartjnl-2018-313476
  2. Maron B.J., Gardin J.M., Flack J.M. et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995; 92 (4): 785–9. DOI: 10.1161/01.cir.92.4.785
  3. Bottega N., Malhamé I., Guo L. et al. Secular trends in pregnancy rates, delivery outcomes, and related health care utilization among women with congenital heart disease. Congenit Heart Dis. 2019; 14: 735–44. DOI: 10.1111/chd.12811
  4. Gipertroficheskaja kardiomiopatija. Klinicheskie rekomendatsii. Rossijskoe kardiologicheskoe obschestvo. 2020; 151 c. [Elektronnyj resurs] [Hypertrophic cardiomyopathy. Clinical guidelines of the Russian cardiology society. 2020;151r. [Electronic resource] (in Russ.)]. URL: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_Kardiomiopatiya.pdf
  5. Diagnostika i lechenie serdechno-sosudistyh zabolevaniĭ pri beremennosti 2018. Natsional'nye rekomendatsii. Rossijskij kardiologicheskij zhurnal. 2018; 3: 91–134 [Diagnosis and treatment of cardiovascular diseases during pregnancy 2018. National guidelines. Russian Journal of Cardiology. 2018; 3: 91–134 (in Russ.)]. DOI: 10.15829/1560-4071-2018-3-91-134
  6. Regitz-Zagrosek V., Roos-Hesselink J.W., Bauersachs J. et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39 (34): 3165–241. DOI: 10.1093/eurheartj/ehy340
  7. Ommen S.R., Mital S., Burke M.A. et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142 (25): e533–e557. DOI: 10.1161/CIR.0000000000000938
  8. Elliott P.M., Anastasakis A., Borger M.A. et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35 (39): 2733–79. DOI: 10.1093/eurheartj/ehu284
  9. van Hagen I.M., Roos-Hesselink J.W. Pregnancy in congenital heart disease: risk prediction and counselling. Heart. 2020; 106: 1853–61. DOI: 10.1136/heartjnl-2019-314702
  10. Narayanan M., Elkayam U., Naqvi T.Z. Echocardiography in Pregnancy: Part 2. Curr Cardiol Rep. 2016; 18 (9): 90. DOI: 10.1111/echo.13242
  11. Vatutin N.T., Taradin G.G., Taratorina A.A. i dr. Ishemicheskaja bolezn' serdtsa i beremennost'. Mediko-sotsial'nye problemy sem'i. 2013; 18 (4): 97–106 [Vatutin N.T., Taradin G.G., Taratorina A.A. et al. Coronary artery disease and pregnancy. Medical and Social Problems of The Family. 2013; 18 (4): 97–106 (in Russ.)].
  12. Gorohova C.G., Morozova T.E., Arakeljants A.A. i dr. Algoritm ehokardiograficheskogo issledovanija u beremennyh. Rossijskij kardiologicheskij zhurnal. 2018; 12: 75–82 [Gorokhova S.G., Morozova T.E., Arakelyants A.A. et al. Algorithm for echocardiographic research in pregnant women. Russian Journal of Cardiology. 2018; 12: 75–82 (in Russ.)]. DOI: 10.15829/1560-4071-2018-12-75-82
  13. van Hagen I.M., Elkayam U., Goland S. et al. Hypertrophic Cardiomyopathy and Pregnancy. In: Cardiac Problems in Pregnancy, 4th Ed. Ed. by U. Elkayam. 2020; 12: r. 167–80.
  14. Avila W.S., Amaral F.M., Ramires J.A. et al. Influence of pregnancy on clinical course and fetal outcome of women with hypertrophic cardiomyopathy. Arq Bras Cardiol. 2007; 88 (4): 480–5. DOI: 10.1590/s0066-782x2007000400019
  15. Vatutin N.T., Taradin G.G., Maron M.S. Gipertroficheskaja kardiomiopatija: geneticheskie izmenenija, patogenez i patofiziologija. Rossijskij kardiologicheskij zhurnal. 2014; 5: 35–42 [Vatutin N.T., Taradin G.G., Maron M.S. Hypertrophic cardiomyopathy: genetic alterations, pathogenesis and pathophysiology. Russian Journal of Cardiology. 2014; 5: 35–42 (in Russ.)]. DOI: 10.15829/1560-4071-2014-5-35-42
  16. Krjuchkova O.N., Kucherenko T.V., Kucherenko E.A. i dr. Gipertroficheskaja kardiomiopatija, sovremennoe sostojanie problemy. Osobennosti vedenija beremennosti i rodov. Krymskij terapevticheskij zhurnal. 2020; 2: 17–20 [Kryuchkova O.N., Kucherenko Yu.A., Kucherenko T.V. et al. Hypertrophic cardiomyopathy. The current state of the problem. Features of pregnancy and childbirth. Crimean Therapeutic Journal. 2020; 2: 17–20 (in Russ.)].
  17. McLeod C.J., Ackerman M.J., Nishimura R.A. et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll Cardiol. 2009; 54 (3): 229–33. DOI: 10.1016/j.jacc.2009.02.071
  18. Pandian N.G., Rowin E.J., Gonzalez A.M. et al. Echocardiographic profiles in hypertrophic cardiomyopathy: imaging beyond the septum and systolic anterior motion. Echo Res Pract. 2015; 2 (1): E1–E7. DOI: 10.1530/ERP-15-0009
  19. Hinojar R., Zamorano J.L., Gonzalez Gomez A. et al. ESC sudden-death risk model in hypertrophic cardiomyopathy: incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients. Clin Cardiol. 2017; 40 (10): 853–60. DOI: 10.1002/clc.22735
  20. Ignatenko G.A., Taradin G.G., Vatutin N.T. i dr. Fibrilljatsija predserdij pri gipertroficheskoj kardiomiopatii. Arhiv' vnutrennej meditsiny. 2021; 11 (3): 173–85 [Ignatenko G.A., Taradin G.G., Vatutin N.T. et al. Atrial fibrillation in hypertrophic cardiomyopathy. The Russian Archives of Internal Medicine. 2021; 11 (3): 173–85 (in Russ.)]. DOI: 10.20514/2226-6704-2021-11-3-173-185
  21. Autore C., Conte M.R., Piccininno M. et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 40 (10): 1864–9. DOI: 10.1016/s0735-1097(02)02495-6
  22. Thaman R., Varnava A., Hamid M.S. et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. Heart. 2003; 89 (7): 752–6. DOI: 10.1136/heart.89.7.752
  23. Walker D., Kaur N., Bell R. et al. Hypertrophic obstructive cardiomyopathy and pregnancy: University College London Hospital experience. Minerva Anestesiol. 2007; 73: 485–6.
  24. Schuler P.K., Herrey A., Wade A. et al. Pregnancy outcome and management of women with an implantable cardioverter defibrillator: a single centre experience. Europace. 2012; 14 (12): 1740–5. DOI: 10.1093/europace/eus172
  25. Tanaka H., Kamiya C., Katsuragi S. et al. Cardiovascular events in pregnancy with hypertrophic cardiomyopathy. Circ J. 2014; 78 (10): 2501–6. DOI: 10.1253/circj.cj-14-0541
  26. Ashikhmina E., Farber M.K., Mizuguchi K.A. Parturients with hypertrophic cardiomyopathy: case series and review of pregnancy outcomes and anesthetic management of labor and delivery. Int J Obstet Anesth. 2015; 24: 344–55. DOI: 10.1016/j.ijoa.2015.07.002
  27. Goland S., van Hagen I., Elbaz-Greener G. et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry for Pregnancy and Cardiac disease (ROPAC). Eur Heart J. 2017; 38 (35): 2683–90. DOI: 10.1093/eurheartj/ehx189
  28. Billebeau G., Etienne M., Cheikh-Khelifa R. et al. Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. Arch Cardiovasc Dis. 2018; 111 (3): 199–209. DOI: 10.1016/j.acvd.2017.05.010
  29. Schinkel A.F. Pregnancy in women with hypertrophic cardiomyopathy. Cardiol Rev. 2014; 22 (5): 217–22. DOI: 10.1097/CRD.0000000000000010
  30. Assamti M., Bougrine R., Ismaili N. et al. Management and outcome of hypertrophic obstructive cardiomyopathy in pregnant women: a case report. Pan Afr Med J. 2021; 38: 140. DOI: 10.11604/pamj.2021.38.140.25699
  31. Mravjan C.R., Petruhin V.A., Pronina V.P. i dr. Gipertroficheskaja kardiomiopatija i beremennost': «zmeja v trave». Rossijskij vestnik akushera-ginekologa. 2009; 6: 70–4 [Mravyan S.R., Petrukhin V.A., Pronina V.P. et al. Hypertrophic cardiomyopathy and pregnancy: «Snake in the grass». Russian Bulletin of Obstetrician Gynecologist. 2009; 6: 70–4 (in Russ.)].
  32. Mravjan C.R., Petruhin V.A., Pronina V.P. i dr. Gipertroficheskaja kardiomiopatija i beremennost': «zmeja v trave»-2. Rossijskij vestnik akushera-ginekologa. 2012; 6: 104–7 [Mravyan S.R., Petrukhin V.A., Pronina V.P. et al. Hypertrophic cardiomyopathy and pregnancy: «snake in the grass»-2. Russian Bulletin of Obstetrician Gynecologist. 2012; 6: 104–7 (in Russ.)].
  33. Koloskova N.N., Aleksandrova S.A., Berseneva M.I. i dr. Tromboz levogo zheludochka u rozhenitsy s gipertroficheskoj obstruktivnoj kardiomiopatiej posle beremennosti, indutsirovannoĭ ekstrakorporal'nym oplodotvoreniem. Kreativnaja kardiologija. 2016; 10 (3): 251–7 [Koloskova N.N., Alexandrova S.A., Berseneva M.I. et al. Left ventricular thrombosis in a woman in labor with hypertrophic obstructive cardiomyopathy after IVF-induced pregnancy. Creative cardiology. 2016; 10 (3): 251–7 (in Russ.)].
  34. Tselujko V.I., Budkova E.A., Daghar S. i dr. Beremennost' pri obstruktivnoj gipertroficheskoj kardiomiopatii. Meditsina neotlozhnyh sostojanij. 2014; 3 (58): 141–7 [Tseluyko V.I., Budkova E.A., Daghar S. et al. Pregnancy in obstructive hypertrophic cardiomyopathy. Emergency medicine. 2014; 3 (58): 141–7 (in Russ.)].
  35. O’Mahony C., Lambiase P.D., Quarta G. et al. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart. 2012; 98 (2): 116–25. DOI: 10.1136/hrt.2010.217182
  36. Jaeggi E.T., Carvalho J.S., De Groot E. et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation. 2011; 124 (16): 1747–54. DOI: 10.1161/CIRCULATIONAHA.111.026120
  37. Tromp C.H., Nanne A.C., Pernet P.J. et al. Electrical cardioversion during pregnancy: safe or not? Neth Heart J. 2011; 19 (3): 134–6. DOI: 10.1007/s12471-011-0077-5
  38. Barnes E.J., Eben F., Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG. 2002; 109 (12): 1406–7.
  39. Tanaka K., Tanaka H., Kamiya C. et al. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 2016; 80 (10): 2221–6. DOI: 10.1253/circj.CJ-15-0617